Previous 10 | Next 10 |
- HM43239 clinical remission at 120mg expands list of potential treatable AML populations - - On track to initiate genotype-enriched expansion program for HM43239 in 2H22 - - Cash runway into fourth quarter of 2023 - - Conference call and webcast at 5:00 pm ET to...
Aptose Biosciences (NASDAQ:APTO) is scheduled to announce Q4 earnings results on Tuesday, March 22nd, after market close. The consensus EPS Estimate is -$0.17 Over the last 3 months, EPS estimates have seen 1 upward revision and 2 downward. For further details see: Aptose Biosciences Q4...
ADBE, AIR, APTO, AVGR, CLBS, GAN, HQY, OTCQB:NEXCF, PAGS, PAYS, POSH, SLDP, WOR, ZY For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Tuesday's close
SAN DIEGO and TORONTO, March 08, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the year and q...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! In preparation for another busy day of trading, we’ve put together a list of the biggest pre-market stock movers for Thursday! Source: ventdusud / Shutterstock.com We’ve got ear...
SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, Presiden...
A lack of progress in the clinic, including another disappointing ASH meeting, has led investors to bail out of this risky early-stage biotech. A new formulation of luxeptinib, and potentially greater exposure to the drug, may finally unlock the potential of this once-promising drug, ...
— H.C. Wainwright BIOCONNECT Virtual Conference — — 11th Annual LifeSci Partners Corporate Access Event — SAN DIEGO and TORONTO, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today...
-- Clinical development of the MYC repressor APTO-253 will be discontinued -- -- Company will focus on advancing kinome inhibitor pipeline -- SAN DIEGO and TORONTO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) ...
Aptose Biosciences (TSX:APS) (NASDAQ:APTO) shares climbed 17% on Thursday after losing up to 45% earlier this week. This came after the company announced results from its leukemia drug trial. What happened? Shares of Aptose were already in free fall before this recen...
News, Short Squeeze, Breakout and More Instantly...
Aptose Biosciences Inc. Company Name:
APTO Stock Symbol:
NASDAQ Market:
Aptose Biosciences Inc. Website:
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, t...
SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies,...
TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML TUS Monotherapy and TUS+VEN Doublet Therapy Active in...